Free tool
FAERS Monitor: Adcetris
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 125388 or its brand name (Adcetris, Brentuximab Vedotin). Reports on generic versions are filed under their own applications.
Reports
10,402
Serious
9,478
91% of reports
Hospitalization
3,931
Death reported
1,994
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use1,358
- febrile neutropenia776
- neuropathy peripheral725
- pyrexia694
- neutropenia599
- death594
- hodgkin^s disease462
- nausea407
- anaemia399
- thrombocytopenia388
- diarrhoea387
- drug ineffective378
- disease progression352
- weight decreased326
- pneumonia325
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2011 | 16 |
| 2012 | 151 |
| 2013 | 182 |
| 2014 | 294 |
| 2015 | 377 |
| 2016 | 453 |
| 2017 | 609 |
| 2018 | 677 |
| 2019 | 887 |
| 2020 | 940 |
| 2021 | 927 |
| 2022 | 821 |
| 2023 | 855 |
| 2024 | 1,517 |
| 2025 | 1,040 |
| 2026 | 656 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,043,757 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| febrile neutropeniaSignal | 776 | 23.9 | 22.3 | 16,875 |
| neuropathy peripheralSignal | 725 | 15.5 | 14.5 | 9,805 |
| neutropeniaSignal | 599 | 8.9 | 8.3 | 4,227 |
| thrombocytopeniaSignal | 388 | 7.0 | 6.4 | 2,007 |
| disease progressionSignal | 352 | 6.0 | 5.4 | 1,476 |
| anaemiaSignal | 399 | 4.2 | 3.8 | 990 |
| pyrexiaSignal | 694 | 4.1 | 3.8 | 1,622 |
| off label useSignal | 1,358 | 3.1 | 3.0 | 2,060 |
| weight decreasedSignal | 326 | 2.4 | 2.1 | 258 |
| pneumoniaSignal | 325 | 2.0 | 1.8 | 171 |
| death | 594 | 1.4 | 1.3 | 69 |
| diarrhoea | 387 | 1.2 | 1.1 | 15 |
| nausea | 407 | 1.0 | 0.9 | 1 |
| drug ineffective | 378 | 0.6 | 0.5 | 122 |
| hodgkin^s disease | 462 | 0.0 | 0.0 | 932,646 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.